Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> BACKGROUND AND PURPOSE</h3><p>Neutrophil overactivation is crucial in the pathogenesis of acute lung injury (ALI). Bletinib (3,3'-dihydroxy-2',6'-bis(<i>p</i>-hydroxybenzyl)-5-methoxybibenzyl), a natural bibenzyl first extracted from <i>Bletilla striata</i> in 1983, has anti-inflammatory, antibacterial, and antimitotic potential. In this study, we evaluated the therapeutic effects of Bletinib in human neutrophilic inflammation and lipopolysaccharide (LPS)-mediated ALI. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> EXPERIMENTAL APPROACH</h3><p>We assessed integrin expression, superoxide anion production, degranulation, neutrophil extracellular trap (NET) formation, and adhesion in activated human neutrophils through flow cytometry, spectrophotometry, and immunofluorescence microscopy. Moreover, phosphorylation of Src family kinases (SFKs) and downstream proteins was evaluated through immunoblotting. Finally, a murine LPS-induced ALI model was used to investigate the potential therapeutic effects of Bletinib treatment.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> KEY RESULTS</h3><p>In activated human neutrophils, Bletinib reduced degranulation, respiratory burst, NET formation, adhesion, migration, and integrin expression; suppressed the enzymatic activity of SFKs, including Src, Lyn, Fgr, and Hck; and inhibited the phosphorylation of SFKs as well as Vav and Bruton's tyrosine kinase (Btk). In our mice with ALI, the pulmonary sections demonstrated considerable amelioration of prominent inflammatory changes, such as haemorrhage, pulmonary oedema, and neutrophil infiltration, after Bletinib treatment.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> CONCLUSION AND IMPLICATIONS</h3><p>This is the first study to provide evidence that Bletinib regulates neutrophilic inflammation by inhibiting the SFKs-Btk-Vav pathway and that Bletinib ameliorates LPS-induced ALI in mice. Further biochemical optimisation of Bletinib may be a promising strategy for the development of novel therapeutics for inflammatory diseases.</p></section>

Targeting allosteric site of AKT by 5,7-dimethoxy-1,4-phenanthrenequinone suppresses neutrophilic inflammation

Penehyclidine Hydrochloride Attenuates LPS-induced Acute Lung Injury Involvement of NF-kappaB Pathway.

MitoQ Protects Against Hyperpermeability of Endothelium Barrier in Acute Lung Injury Via a Nrf2-dependent Mechanism

Inhibition of Myosin Light-Chain Kinase Enhances the Clearance of Lipopolysaccharide-Induced Lung Inflammation Possibly by Accelerating Neutrophil Apoptosis.

Knockdown of CXCL1 Improves ACLF by Reducing Neutrophil Recruitment to Attenuate ROS Production and Hepatocyte Apoptosis.

Inhaled Neutrophil Elastase Inhibitor Alleviates Lipopolysaccharide Triggers Neutrophil Extracellular Trap-Mediated Acute Lung Injury via the MAPK/AKT/NLRP3 Pathway

Inhibition of protein kinase C alpha attenuates lipopolysaccharide-triggered acute lung injury by alleviating the hyperinflammatory response and oxidative stress

A CRTH2 Antagonist, CT-133, Suppresses NF-κB Signalling to Relieve Lipopolysaccharide-Induced Acute Lung Injury.

Knockdown of phosphoinositide-dependent kinase 1 (PDK1) inhibits fibrosis and inflammation in lipopolysaccharide-induced acute lung injury rat model by attenuating NF-κB/p65 pathway activation

Bletinib ameliorates neutrophilic inflammation and lung injury by inhibiting Src family kinase phosphorylation and activity

MNK as a potential pharmacological target for suppressing LPS-induced acute lung injury in mice

Kaempferol Reduces K63-linked Polyubiquitination to Inhibit Nuclear Factor-Κb and Inflammatory Responses in Acute Lung Injury in Mice.

Targeting TLR4 and regulating the Keap1/Nrf2 pathway with andrographolide to suppress inflammation and ferroptosis in LPS-induced acute lung injury

RIPK1 inhibitor ameliorates pulmonary injury by modulating the function of neutrophils and vascular endothelial cells

Topotecan Alleviates Lipopolysaccharide-Mediated Acute Lung Injury Via the NF-κB Signaling Pathway

Physalin H ameliorates LPS-induced acute lung injury via KEAP1/NRF2 axis

Non-muscle Myosin Light Chain Kinase Isoform is a Viable Molecular Target in Acute Inflammatory Lung Injury.

Chlorogenic acid reduces inflammation by inhibiting the elevated expression of KAT2A to ameliorate lipopolysaccharide‐induced acute lung injury

Selective activation of PFKL suppresses the phagocytic oxidative burst

α-Ketoglutarate Modulates Macrophage Polarization Through Regulation of PPARγ Transcription and mTORC1/p70S6K Pathway to Ameliorate ALI/ARDS.

Targeted degradation of hexokinase 2 for anti‐inflammatory treatment in acute lung injury